Imexpharm Corp 2025 Annual Report with Sustainability Disclosures
Company: Imexpharm Corp
Sector: Manufacturing
Country: Vietnam
Year: 2025
Type: Annual Report with Sustainability Disclosures
Pages: 144
The report highlights the company's strong 2025 growth, with gross revenue reaching VND 2,914.3 billion and the launch of IMECEF, Vietnam's first EU-GMP first generic antibiotic. It also reports a stable workforce of 1,456 employees supported by extensive training and development. Environmental disclosures include 1,198 tCO2e of Scope 1 emissions, 11,945 tCO2e of Scope 2 emissions, and 101,214 m3 of water consumption.
Data Services
From bulk PDFs to structured indicators and machine-readable documents.